

DRUG-RESISTANT TUBERCULOSIS: The Time to Act is Now



Drug-resistant TB (DR-TB) is on the rise with 558,000 new cases a year. It is the only **AIRBORNE** drug-resistant epidemic and responsible for nearly 1/3 of all deaths from antimicrobial resistance globally.



UNDERSERVED COMMUNITIES BEAR THE LARGEST BURDEN.

DR-TB impacts people in their most economically productive years, between 25 to 34-years-old, and drives catastrophic costs to households,

LOCKING GENERATIONS INTO A CYCLE OF POVERTY.




Economic Impact from TB on patients and their households

Cost Burden¹



58%
drop in
annual income

What are the costs?



60% income loss
20% direct medical costs
20% direct non-medical costs

Tanimura T, Jaramillo E, Weil D, et al. Financial burden for tuberculosis patients in low- and middle-income countries: A systematic review. European Respiratory Journal. 2014;43(6):1763-75.



By tolerating a situation in which **MILLIONS OF PEOPLE WITH TB** are either **UNTREATED**, or treated [incorrectly], we are enabling a **SIGNIFICANT THREAT TO GLOBAL HEALTH SECURITY** to loom ever larger.”
-Peter Sands, *Executive Director, The Global Fund*

DR-TB WEAKENS THE GLOBAL ECONOMY...



US\$17.8 BILLION ...HINDERS

Future GDP loss globally from DR-TB deaths in a single year

INDIA: 41%
OF GLOBAL LOSS
(US\$7.3 billion)



UNIVERSAL HEALTH COVERAGE...

2/3 PEOPLE living with DR-TB are missed by health systems each year

...THREATENS GLOBAL HEALTH SECURITY

EBOLA IN WEST AFRICA OVER 3 YEARS VS. DR-TB IN 2017

29,000 cases

558,000 cases (20x)



11,000 deaths

230,000 deaths



SUPPORT THE END OF DR-TB

World leaders have committed to treat 1.5 million DR-TB patients by 2022. A successful Global Fund replenishment offers the opportunity to accelerate these efforts by securing the US\$2.5 billion needed to dramatically increase diagnosis and treatment of TB and DR-TB.

DR-TB is a winnable fight. Together, we can create a world without TB.

www.jnj.com/TB | www.eiu.com/Drug-Resistant-TB